Last reviewed · How we verify
Antipsychotic treatment
Antipsychotic treatment is a Antipsychotic Small molecule drug developed by Fundación Pública Andaluza Progreso y Salud. It is currently in Phase 3 development for Schizophrenia, Bipolar disorder, Psychotic disorders. Also known as: Antipsychotic drugs.
Antipsychotic treatment works by modulating dopamine and/or serotonin neurotransmission in the brain to reduce psychotic symptoms.
Antipsychotic treatment is used to manage conditions such as schizophrenia and schizoaffective disorder, as well as complications like metabolic evaluation and cardiac complications. The treatment typically involves small molecule interventions, including medications like quetiapine, which are studied in clinical trials to evaluate their efficacy and safety.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Antipsychotic treatment |
|---|---|
| Also known as | Antipsychotic drugs |
| Sponsor | Fundación Pública Andaluza Progreso y Salud |
| Drug class | Antipsychotic |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology |
| Phase | Phase 3 |
Mechanism of action
Antipsychotics typically block dopamine D2 receptors and/or serotonin 5-HT2A receptors, reducing hyperactivity in mesolimbic and mesocortical pathways associated with psychosis. This mechanism helps alleviate positive symptoms such as hallucinations and delusions, and some agents also improve negative symptoms and cognitive dysfunction.
Approved indications
- Schizophrenia
- Bipolar disorder
- Psychotic disorders
Common side effects
- Extrapyramidal symptoms (EPS)
- Weight gain
- Metabolic syndrome
- Hyperprolactinemia
- Sedation
- Orthostatic hypotension
Key clinical trials
- Incentives and Long-Acting Injectable Adherence After Involuntary Hospitalization (NA)
- Immune Mechanisms of Antipsychotic Treatment Response
- Cue-based Intervention in Prospective Memory and Medication Adherence. (NA)
- Cerebellum-based Imaging Neural Markers for Antipsychotic Response
- Psychiatric Multi-omics and Neuroimaging Project
- Cognitive Impairment Characteristics and Biological Mechanisms in Untreated Severe Mental Illness
- Medication Adherence in Severe Mental Illness: a Promotion Program (NA)
- Pharmacist-led Interventions in Psychiatric Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antipsychotic treatment CI brief — competitive landscape report
- Antipsychotic treatment updates RSS · CI watch RSS
- Fundación Pública Andaluza Progreso y Salud portfolio CI
Frequently asked questions about Antipsychotic treatment
What is Antipsychotic treatment?
How does Antipsychotic treatment work?
What is Antipsychotic treatment used for?
Who makes Antipsychotic treatment?
Is Antipsychotic treatment also known as anything else?
What drug class is Antipsychotic treatment in?
What development phase is Antipsychotic treatment in?
What are the side effects of Antipsychotic treatment?
Related
- Drug class: All Antipsychotic drugs
- Manufacturer: Fundación Pública Andaluza Progreso y Salud — full pipeline
- Therapeutic area: All drugs in Psychiatry/Neurology
- Indication: Drugs for Schizophrenia
- Indication: Drugs for Bipolar disorder
- Indication: Drugs for Psychotic disorders
- Also known as: Antipsychotic drugs
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing